This example is also representative of a wider issue: given the complexity of NF-κB function in the immune system it is perhaps prohibitively difficult to predict the outcome of systemic IKKβ inhibition on anti-tumour immunity, thus limiting the potential of IKKβ inhibitors as adjuncts to cancer immunotherapies. The gene discussed is NFKB1; the disease is cancer.